AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18347776 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 50
Study 18347776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 15950139 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD patients with previous diagnosis
Number of subjects: 363
Study 15950139 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD patients with worse lung function and HRQL
Number of subjects: 363
Study 15950139 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD patients with chronic symptoms
Number of subjects: 363
Study 15950139 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD in never smokers
Number of subjects: 363
Study 15950139 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheezing as a symptom
Number of subjects: 363
Study 12190134 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ketorolac + 15 mg codeine phosphate
Number of subjects: 67
Study 12190134 — intervention group
Group type: COMPARATOR
Intervention: Codeine alone
Number of subjects: 67
Study 12190134 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ketorolac + codeine
Number of subjects: 67
Study 12190134 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine in combination
Number of subjects: 67
Study 10655291 — intervention group
Group type: EXPERIMENTAL
Intervention: Follitropin alpha (Gonal-F)
Number of subjects: 296
Study 10655291 — intervention group
Group type: COMPARATOR
Intervention: Follitropin beta (Puregon)
Number of subjects: 296
Study 8882400 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation (0.8 mg of folic acid daily)
Number of subjects: 4862
Study 8882400 — intervention group
Group type: COMPARATOR
Intervention: Trace element supplement (placebo-like)
Number of subjects: 4862
Study 1519784 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl 50 micrograms.h‐1
Number of subjects: 95
Study 1519784 — intervention group
Group type: COMPARATOR
Intervention: Transdermal fentanyl 25 micrograms.h‐1
Number of subjects: 95
Study 1519784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 6831829 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 500 mg acetaminophen and 65 mg caffeine
Number of subjects: 1518
Study 6831829 — intervention group
Group type: COMPARATOR
Intervention: 500 mg acetaminophen alone
Number of subjects: 1518
Study 6831829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1518
Study 31418532 — intervention group
Group type: EXPERIMENTAL
Intervention: Brochure about venous disease and compression therapy (case group)
Number of subjects: 136
Study 31418532 — intervention group
Group type: COMPARATOR
Intervention: No brochure (control group)
Number of subjects: 136
Study 28848056 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-on education
Number of subjects: 39
Study 28848056 — intervention group
Group type: COMPARATOR
Intervention: Online education
Number of subjects: 39
Study 27282543 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy norm condition
Number of subjects: 204
Study 27282543 — intervention group
Group type: COMPARATOR
Intervention: Unhealthy norm condition
Number of subjects: 204
Study 27282543 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthiness norm
Number of subjects: 204
Study 24749634 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential avoidance during self-disclosure conversation
Number of subjects: 75
Study 24749634 — intervention group
Group type: COMPARATOR
Intervention: Experiential avoidance during small-talk conversation
Number of subjects: 75
Study 24749634 — intervention group
Group type: EXPERIMENTAL
Intervention: Momentary experiential avoidance in everyday life
Number of subjects: 75
Study 24749634 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity to situational threat
Number of subjects: 75
Study 22502624 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% copaiba essential oil preparation
Number of subjects: 0
Study 22502624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20527063 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic fields
Number of subjects: 24
Study 20527063 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 24
Study 18585701 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg/day
Number of subjects: 120
Study 18585701 — intervention group
Group type: COMPARATOR
Intervention: Control (therapeutic lifestyle modification)
Number of subjects: 120
Study 16059597 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromazepam 6 mg
Number of subjects: 26
Study 16059597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 12377643 — intervention group
Group type: EXPERIMENTAL
Intervention: irinotecan + leucovorin (LV)/5‐fluorouracil (5‐FU)
Number of subjects: 101
Study 12377643 — intervention group
Group type: EXPERIMENTAL
Intervention: oxaliplatin + LV/5‐FU
Number of subjects: 101
Study 12377643 — intervention group
Group type: EXPERIMENTAL
Intervention: irinotecan + oxaliplatin
Number of subjects: 101
Study 10348287 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive doxorubicin-containing chemotherapy and whole-lung irradiation
Number of subjects: 90
Study 10348287 — intervention group
Group type: COMPARATOR
Intervention: Less aggressive treatment with 2 or 3 drugs without whole-lung irradiation
Number of subjects: 90
Study 7586616 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 20 mg
Number of subjects: 12
Study 7586616 — intervention group
Group type: COMPARATOR
Intervention: Ovine corticotrophin‐releasing hormone (oCRH) 1 microgram/kg
Number of subjects: 12
Study 7586616 — intervention group
Group type: COMPARATOR
Intervention: Insulin 0.15U/kg
Number of subjects: 12
Study 1849413 — intervention group
Group type: EXPERIMENTAL
Intervention: AVE‐5 regimen (etoposide 60 mg/m2 IV on day 1 and 120 mg/m2 orally on days 2-5)
Number of subjects: 78
Study 1849413 — intervention group
Group type: COMPARATOR
Intervention: AVE‐1 regimen (etoposide 300 mg/m2 IV on day 1)
Number of subjects: 78
Study 6418074 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemo-endocrine therapy (TAM+) with Mitomycin-C plus Tegafur and Tamoxifen 20 mg/day
Number of subjects: 40
Study 6418074 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (TAM-)
Number of subjects: 40
Study 6418074 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemo-endocrine therapy (TAM+) in curatively resected cases
Number of subjects: 40
Study 6418074 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (TAM-) in curatively resected cases
Number of subjects: 40
Study 30693573 — intervention group
Group type: EXPERIMENTAL
Intervention: AL-335 800 mg, odalasvir 25 mg, and simeprevir 75 mg once daily for 6 weeks
Number of subjects: 365
Study 30693573 — intervention group
Group type: EXPERIMENTAL
Intervention: AL-335 800 mg, odalasvir 25 mg, and simeprevir 75 mg once daily for 8 weeks
Number of subjects: 365
Study 30693573 — intervention group
Group type: COMPARATOR
Intervention: Historical control (not specified in detail)
Number of subjects: 365
Study 29138049 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise (TE) program consisting of motor control, stretching, and aerobic exercises
Number of subjects: 56
Study 29138049 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain neurophysiology education (PNE) plus therapeutic exercise (TE)
Number of subjects: 56
Study 29138049 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic exercise (TE) alone
Number of subjects: 56
Study 27267785 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone rapidly dissolving tablets
Number of subjects: 313
Study 27267785 — intervention group
Group type: COMPARATOR
Intervention: Generic buprenorphine
Number of subjects: 313
Study 25144188 — intervention group
Group type: COMPARATOR
Intervention: Event-related potentials (ERPs) in LD NOS children during a semantic judgment priming task.
Number of subjects: 41
Study 25144188 — intervention group
Group type: COMPARATOR
Intervention: Control group during a semantic judgment priming task.
Number of subjects: 41
Study 18925521 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis
Number of subjects: 0
Study 15083484 — intervention group
Group type: EXPERIMENTAL
Intervention: New treatment
Number of subjects: 0
Study 15083484 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study 11236267 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 40
Study 11236267 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic sclerotherapy
Number of subjects: 40
Study 9296936 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women with hypertension
Number of subjects: 62
Study 9296936 — intervention group
Group type: COMPARATOR
Intervention: Healthy pregnant women (control group)
Number of subjects: 62
Study 8253920 — intervention group
Group type: EXPERIMENTAL
Intervention: Human chorionic gonadotrophin (HCG)
Number of subjects: 60
Study 8253920 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular progesterone
Number of subjects: 60
Study 3122276 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 50
Study 3122276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 31336393 — intervention group
Group type: EXPERIMENTAL
Intervention: Î±‐tocopherol acetate (150mg/L)
Number of subjects: 360
Study 31336393 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinus ponderosa leaves (150mg/L)
Number of subjects: 360
Study 31336393 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Pinus ponderosa leaves (70mg) and Î±‐tocopherol acetate (70mg)
Number of subjects: 360
Study 31336393 — intervention group
Group type: COMPARATOR
Intervention: Control group (IC)
Number of subjects: 360
Study 27986684 — intervention group
Group type: EXPERIMENTAL
Intervention: RG-TFV rectal gel daily
Number of subjects: 195
Study 27986684 — intervention group
Group type: EXPERIMENTAL
Intervention: RG-TFV rectal gel before and after receptive anal intercourse (RAI)
Number of subjects: 195
Study 27986684 — intervention group
Group type: COMPARATOR
Intervention: Daily gel regimen
Number of subjects: 195
Study 27078991 — intervention group
Group type: EXPERIMENTAL
Intervention: Floating needle therapy
Number of subjects: 108
Study 27078991 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 108
Study 27078991 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 24835833 — intervention group
Group type: EXPERIMENTAL
Intervention: UMEC 125 μg plus VI 25 μg
Number of subjects: 2332
Study 24835833 — intervention group
Group type: EXPERIMENTAL
Intervention: UMEC 62.5 μg plus VI 25 μg
Number of subjects: 2332
Study 24835833 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 2332
Study 24835833 — intervention group
Group type: COMPARATOR
Intervention: UMEC plus VI
Number of subjects: 2332
Study 24835833 — intervention group
Group type: COMPARATOR
Intervention: TIO
Number of subjects: 2332
Study 22654431 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole (20 mg twice daily)
Number of subjects: 83
Study 22654431 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (300 mg twice daily)
Number of subjects: 83
Study 22654431 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Number of subjects: 83
Study 22654431 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 83
Study 19626811 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal 1.25 mg hyperbaric bupivacaine plus cerebrospinal fluid 0.75 ml
Number of subjects: 70
Study 19626811 — intervention group
Group type: COMPARATOR
Intervention: Propofol 1‐1.5 mg/kg IV bolus dose and 6‐10 mg/kg/hr infusion
Number of subjects: 70
Study 17366527 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily ceftriaxone plus amikacin (C + A)
Number of subjects: 129
Study 17366527 — intervention group
Group type: COMPARATOR
Intervention: Imipenem monotherapy (control)
Number of subjects: 129
Study 15270930 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention including a mass media campaign and information to women visiting family planning clinics.
Number of subjects: 800
Study 15270930 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no specific intervention details provided).
Number of subjects: 800
Study 11568992 — intervention group
Group type: EXPERIMENTAL
Intervention: eNO measurement in mild intermittent asthmatic children (5.6 +/- 0.4 ppb)
Number of subjects: 84
Study 11568992 — intervention group
Group type: COMPARATOR
Intervention: eNO measurement
Number of subjects: 84
Study 9442542 — intervention group
Group type: EXPERIMENTAL
Intervention: Scavenging at 45 L/min evacuation rate
Number of subjects: 30
Study 8179790 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 26
Study 8179790 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 26
Study 3067809 — intervention group
Group type: EXPERIMENTAL
Intervention: Fencamfamine 25 mg
Number of subjects: 6
Study 3067809 — intervention group
Group type: EXPERIMENTAL
Intervention: Fencamfamine 50 mg
Number of subjects: 6
Study 31948355 — intervention group
Group type: EXPERIMENTAL
Intervention: SCAIL score (symptomatic carotid atheroma inflammation lumen‐stenosis)
Number of subjects: 196
Study 31948355 — intervention group
Group type: EXPERIMENTAL
Intervention: SCAIL score
Number of subjects: 196
Study 31948355 — intervention group
Group type: EXPERIMENTAL
Intervention: SCAIL score after positron emission tomography-imaging
Number of subjects: 196
Study 31948355 — intervention group
Group type: COMPARATOR
Intervention: SCAIL score vs stenosis severity
Number of subjects: 196
Study 31948355 — intervention group
Group type: EXPERIMENTAL
Intervention: SCAIL score in mild or moderate stenosis
Number of subjects: 196
Study 30206342 — intervention group
Group type: EXPERIMENTAL
Intervention: Soymilk for 5 days
Number of subjects: 10
Study 30206342 — intervention group
Group type: COMPARATOR
Intervention: Matched controls (N=10)
Number of subjects: 10
Study 27316632 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 851
Study 27316632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 851
Study 25428655 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct suggestion
Number of subjects: 31
Study 25428655 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect suggestion
Number of subjects: 31
Study 25428655 — intervention group
Group type: COMPARATOR
Intervention: Control (non-suggestive)
Number of subjects: 31
Study 24351501 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants (adequate dose for at least 6 weeks)
Number of subjects: 2439
Study 20602498 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Anaesthesia (LA)
Number of subjects: 0
Study 20602498 — intervention group
Group type: COMPARATOR
Intervention: General Anaesthesia (GA)
Number of subjects: 0
Study 18443395 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous nasal spray 100 microg twice daily
Number of subjects: 34
Study 18443395 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal drop preparation 400 microg once daily
Number of subjects: 34
Study 18443395 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal drop preparation 400 microg twice daily
Number of subjects: 34
Study 18443395 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 34
Study 16788316 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa)
Number of subjects: 40
Study 12669896 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 400 microg
Number of subjects: 309
Study 12669896 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 200 microg
Number of subjects: 309
Study 12669896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 309
Study 10913928 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical hPTH(1-34) therapy (50 microg/day for 28 days in 3-month cycles)
Number of subjects: 29
Study 10913928 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated osteoporotic patients, n = 15)
Number of subjects: 29
Study 8933239 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 18
Study 8933239 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem
Number of subjects: 18
Study 8933239 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol (NYHA class III)
Number of subjects: 18
Study 8933239 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem (NYHA class III)
Number of subjects: 18
Study 8933239 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol (NYHA class IV)
Number of subjects: 18
Study 8933239 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem (NYHA class IV)
Number of subjects: 18
Study 1417010 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegafur suppository preoperatively + tegafur oral preparation postoperatively
Number of subjects: 0
Study 1417010 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegafur suppository preoperatively + UFT oral preparation postoperatively
Number of subjects: 0
Study 1417010 — intervention group
Group type: COMPARATOR
Intervention: Tegafur oral preparation postoperatively
Number of subjects: 0
Study 1417010 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative tegafur administration
Number of subjects: 0
Study 1417010 — intervention group
Group type: EXPERIMENTAL
Intervention: Dukes B patients with preoperative tegafur administration
Number of subjects: 0
Study 3893024 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% Butoconazole nitrate (BN) vaginal cream
Number of subjects: 130
Study 3893024 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% Butoconazole nitrate (BN) vaginal cream
Number of subjects: 130
Study 3893024 — intervention group
Group type: COMPARATOR
Intervention: 2% Miconazole nitrate (MN) vaginal cream
Number of subjects: 130
Study 31272493 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled methoxyflurane (maximum dose of 2 × 3 ml)
Number of subjects: 110
Study 31272493 — intervention group
Group type: COMPARATOR
Intervention: Normal saline placebo (maximum dose 2 × 5 ml)
Number of subjects: 110
Study 31272493 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled methoxyflurane
Number of subjects: 110
Study 30587151 — intervention group
Group type: COMPARATOR
Intervention: 3-month cognitive training program, once per week, consisting of multi-domain and ecological cognitive exercises in small homogenous groups.
Number of subjects: 0
Study 30587151 — intervention group
Group type: COMPARATOR
Intervention: Passive control group (no specific intervention details provided).
Number of subjects: 0
Study 26329381 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (CIT) 20 mg/day for 35 days with anodal tDCS
Number of subjects: 12
Study 26329381 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (CIT) 20 mg/day for 35 days with cathodal tDCS
Number of subjects: 12
Study 26329381 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (CIT) with dextromethorphan (150 mg) and anodal/cathodal tDCS
Number of subjects: 12
Study 26329381 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC) medication with anodal or cathodal tDCS
Number of subjects: 12
Study 24629063 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week exercise intervention with four group sessions and home exercises three times a week, with weekly telephone follow-up during eight weeks without group sessions.
Number of subjects: 0
Study 24629063 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 0
Study 22032832 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (21 mg)
Number of subjects: 42
Study 22032832 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 42
Study 20605552 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy
Number of subjects: 80
Study 20605552 — intervention group
Group type: COMPARATOR
Intervention: Light massage control
Number of subjects: 80
Study 20605552 — intervention group
Group type: COMPARATOR
Intervention: No physical examination (PE)
Number of subjects: 80
Study 20605552 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy and light massage control
Number of subjects: 80
Study 17765899 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical interventions for fistula repair
Number of subjects: 0
Study 16140677 — intervention group
Group type: EXPERIMENTAL
Intervention: Pump On (PO) - 50% of the basal rate
Number of subjects: 10
Study 16140677 — intervention group
Group type: COMPARATOR
Intervention: Pump Off (PF)
Number of subjects: 10
Study 11854632 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal replacement of estradiol and progesterone for 6 weeks
Number of subjects: 30
Study 11854632 — intervention group
Group type: COMPARATOR
Intervention: Nontreated infants
Number of subjects: 30
Study 9883100 — intervention group
Group type: EXPERIMENTAL
Intervention: Dangerous situations
Number of subjects: 0
Study 9883100 — intervention group
Group type: EXPERIMENTAL
Intervention: Careless behavior
Number of subjects: 0
Study 9883100 — intervention group
Group type: EXPERIMENTAL
Intervention: Degree of good luck
Number of subjects: 0
Study 9883100 — intervention group
Group type: EXPERIMENTAL
Intervention: Luck
Number of subjects: 0
Study 7608436 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (5,000 IU) before thrombolytic treatment with saruplase (20 mg bolus + 60 mg infusion over 60 min)
Number of subjects: 118
Study 7608436 — intervention group
Group type: COMPARATOR
Intervention: Placebo before thrombolytic treatment with saruplase (20 mg bolus + 60 mg infusion over 60 min)
Number of subjects: 118
Study 7608436 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (5,000 IU) before thrombolytic treatment with saruplase
Number of subjects: 118
Study 7608436 — intervention group
Group type: COMPARATOR
Intervention: Placebo before thrombolytic treatment with saruplase
Number of subjects: 118
Study 2789272 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil (5‐FU) alone (arm A)
Number of subjects: 265
Study 2789272 — intervention group
Group type: COMPARATOR
Intervention: High‐dose leucovorin plus 5‐FU (arm B)
Number of subjects: 265
Study 2789272 — intervention group
Group type: COMPARATOR
Intervention: Sequential methotrexate, 5‐FU, and leucovorin (arm C)
Number of subjects: 265
Study 342557 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (6 sessions of verbal self-instructions via modeling with response-cost contingent upon errors)
Number of subjects: 20